- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Atea Pharmaceuticals Inc (AVIR)
Atea Pharmaceuticals Inc stock price live, this page displays NASDAQ AVIR stock exchange data. View the AVIR premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Atea Pharmaceuticals Inc real time stock price chart below.
What Is the Atea Pharmaceuticals Inc Stock Price Today?
The Atea Pharmaceuticals Inc stock price today is 4.210.
What Is the Stock Symbol for Atea Pharmaceuticals Inc?
The stock symbol for Atea Pharmaceuticals Inc is "AVIR."
What Stock Exchange Does Atea Pharmaceuticals Inc Trade On?
Atea Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Atea Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Atea Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AVIR quote. (ISIN: US04683R1068)
What Is the Atea Pharmaceuticals Inc Stock Price Today?
The Atea Pharmaceuticals Inc stock price today is 4.210.
What Is the Stock Symbol for Atea Pharmaceuticals Inc?
The stock symbol for Atea Pharmaceuticals Inc is "AVIR."
What Stock Exchange Does Atea Pharmaceuticals Inc Trade On?
Atea Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Atea Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Atea Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AVIR quote. (ISIN: US04683R1068)
NASDAQ
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.090
4.290
52 wk Range
2.870
6.450
AVIR is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.0904.290
52 wk Range
2.8706.450
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
AVIR Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PricePrice Target
8.500
Upside
+101.90%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
Form 8K Atea Pharmaceuticals Inc For: 9 November- Investing.com
- Form 8K Atea Pharmaceuticals Inc For: 9 November
- Investing.com
Form 8K Atea Pharmaceuticals Inc For: 9 November- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Buy
Moving Averages
Sell
Analyst Ratings
2 Buy
1 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 8.500
(+101.90% Upside)
Atea Pharmaceuticals Inc Earnings Call Summary for Q3/2026
- Atea posted Q3 2026 adjusted EPS of -$0.40, beating analyst estimates of -$0.55 by 27.27%, with shares rising 2.32% to $4.41.
- Company secured $200M Hercules Capital credit facility with $65M initial draw, extending cash runway into mid-2028 without equity dilution.
- Lead hepatitis C drug bemnifosbuvir/ruzasvir met phase III primary endpoint with 94% response rate; U.S. NDA filing planned mid-2027.
- Management targets 2028 U.S. commercial launch, positioning 8-week treatment as best-in-class with low drug interactions and no food effect.
- Key 2027 milestones include C-FORWARD top-line results and hepatitis E program AT-587 phase I data, both expected early in the year.
Last Updated: 2026-11-09, 05:18 p/m
Read Full TranscriptEarnings
Latest Release
Nov 09, 2026
EPS / Forecast
-0.40 / -0.55
Revenue / Forecast
-- / --
Compare AVIR to Peers and Sector
Metrics to compare | AVIR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAVIRPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.2x | −4.1x | −0.2x | |
PEG Ratio | 0.20 | −0.18 | 0.00 | |
Price/Book | 1.9x | 1.9x | 2.6x | |
Price / LTM Sales | - | 7.0x | 2.8x | |
Upside (Analyst Target) | 101.9% | 68.4% | 60.5% | |
Fair Value Upside | Unlock | 1.1% | 7.8% | Unlock |
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Atea (AVIR) Stock Price Today?
The Atea stock price today is 4.210 USD.
What Stock Exchange Does Atea Trade On?
Atea is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Atea?
The stock symbol for Atea is "AVIR."
What Is the Atea Market Cap?
As of today, Atea market cap is 338.880M USD.
What Is Atea's Earnings Per Share (TTM)?
The Atea EPS (TTM) is -1.96.
When Is the Next Atea Earnings Date?
Atea will release its next earnings report on Mar 02, 2027.
From a Technical Analysis Perspective, Is AVIR a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
How Many Times Has Atea Stock Split?
Atea has split 0 times.
How Many Employees Does Atea Have?
Atea has 55 employees.
What is the current trading status of Atea (AVIR)?
As of Nov 12, 2026, Atea (AVIR) is trading at a price of 4.210 USD, with a previous close of 4.220 USD. The stock has fluctuated within a day range of 4.090 USD to 4.290 USD, while its 52-week range spans from 2.870 USD to 6.450 USD.
What Is Atea (AVIR) Price Target According to Analysts?
The average 12-month price target for Atea is 8.500 USD, with a high estimate of 10 USD and a low estimate of 7 USD. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +101.90% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.